Last reviewed · How we verify
E6007
At a glance
| Generic name | E6007 |
|---|---|
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis (PHASE2)
- A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants (PHASE1)
- Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects (PHASE1)
- A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E6007 CI brief — competitive landscape report
- E6007 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI